ThePrint on MSN2 天
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...
announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...
announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...
Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a ...
MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...
New Delhi, Dec 11 (PTI) Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder ...
announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...
The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India, the company said.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈